Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6

Blood

Volumn 121, Issue 22, 2013, Pages 4493-4503

  Witzens Harig, Mathias ^a   Hose, Dirk ^a,b   Junger, Simone ^b,c   Pfirschke, Christina ^b,c   Khandelwal, Nisit ^b,c   Umansky, Ludmila ^c   Seckinger, Anja ^a   Conrad, Heinke ^c,d   Brackertz, Bettina ^d   Reme, Thierry ^e,f,g   Gueckel, Brigitte ^h   Meißner, Tobias ^a   Hundemer, Michael ^a   Ho, Anthony D ^a   Rossi, Jean Francois ^e,g   Neben, Kai ^a   Bernhard, Helga ^d,i   Goldschmidt, Hartmut ^a,b   Klein, Bernard ^e,f,g   Beckhove, Philipp ^b,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Nationales Centrum fur Tumorerkrankungen   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e INSERM   (France)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

^g UNIV MONTPELLIER   (France)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ KLINIKUM DARMSTADT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; MELPHALAN; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; TETANUS TOXOID; CEACAM6 PROTEIN, HUMAN; CELL ADHESION MOLECULE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; SURFACE PROPERTY; TUMOR ESCAPE; CELL STRAIN MCF 7; CELL STRAIN U937; CYTOTOXICITY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PATHOLOGY; PLASMA CELL; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION MOLECULES; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; MCF-7 CELLS; MULTIPLE MYELOMA; PLASMA CELLS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; U937 CELLS;

MLCS; MLOWN;

EID: 84880802021     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-429415     Document Type: Article

References (56)

1. Beckhove P, Feuerer M, Dolenc M, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest. 2004;114(1):67-76.
2. Choi C, Witzens M, Bucur M, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood. 2005;105(5):2132-2134.
3. Sommerfeldt N, Schutz F, Sohn C, Forster J, Schirrmacher V, Beckhove P. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res. 2006;66(16):8258-8265.
4. Schmitz-Winnenthal FH, Volk C, Z'graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 2005;65(21): 10079-10087.
5. Jager E, Nagata Y, Gnjatic S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA. 2000;97(9):4760-4765.
6. Romero P, Cerottini JC, Speiser DE. The human T cell response to melanoma antigens. Adv Immunol. 2006;92:187-224.
7. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patientderived reactivated memory T cells from bone marrow. Nat Med. 2001;7(4):452-458.
8. Letsch A, Keilholz U, Assfalg G, Mailander V, Thiel E, Scheibenbogen C. Bone marrow contains melanoma-reactive CD81 effector T cells and, compared with peripheral blood, enriched numbers of melanoma-reactive CD81 memory T cells. Cancer Res. 2003;63(17):5582-5586.
9. Horna P, Sotomayor EM. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets. 2007;7(1):41-53.
10. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 2004;92:13-27.
11. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-2972.
12. Aschan J, Lonnqvist B, Ringden O, Kumlien G, Gahrton G. Graft-versus-myeloma effect. Lancet. 1996;348(9023):346.
13. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood. 1996;87(3): 1196-1198.
14. Le Blanc R, Montminy-Metivier S, Belanger R, et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHDassociated graft-versus-myeloma effect. Bone Marrow Transplant. 2001;28(9):841-848.
15. Bjorkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29(22): 3016-3022.
16. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88(12):4711-4718.
17. Bensinger WI, Buckner D, Gahrton G. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am. 1997;11(1): 147-157.
18. Gahrton G, Svensson H, Cavo M, et al; European Group for Blood and Marrow Transplantation. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113(1):209-216.
19. Barlogie B, Shaughnessy J, Zangari M, Tricot G. High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol. 2002; 29(6 Suppl 17):26-33.
20. Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med. 2003; 197(12):1667-1676.
21. Moss P, Gillespie G, Frodsham P, Bell J, Reyburn H. Clonal populations of CD41 and CD81 T cells in patients with multiple myeloma and paraproteinemia. Blood. 1996;87(8):3297-3306.
22. Brown RD, Yuen E, Nelson M, Gibson J, Joshua D. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia. 1997; 11(8):1312-1317.
23. Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood. 2001;97(6): 1750-1755.
24. Hansson L, Rabbani H, Fagerberg J, Osterborg A, Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood. 2003; 101(12):4930-4936.
25. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA. 2002;99(20):13009-13013.
26. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med. 2003; 198(11):1753-1757.
27. Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol. 2001;125(2):190-197.
28. Thies A, Moll I, Berger J, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20(10):2530-2536.
29. Kaito K, Otsubo H, Takahara S, et al. Carcinoembryonic antigen-producing multiple myeloma detected by a transcription-reverse transcription concerted reaction system. Int J Hematol. 2007;85(2):128-131.
30. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991;5(5):344-366.
31. Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol. 2006;18(5):565-571.
32. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol. 2006;6(6):433-446.
33. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4(2):118-132.
34. Seckinger A, Meissner T, Moreaux J, et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012;120(5): 1087-1094.
35. Hose D, Reme T, Meissner T, et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood. 2009;113(18): 4331-4340.
36. Hose D, Moreaux J, Meissner T, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114(1):128-143.
37. Seckinger A, Meissner T, Moreaux J, et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene. 2009;28(44): 3866-3879.
38. Meissner T, Seckinger A, Reme T, et al. Gene expression profiling in multiple myeloma-reporting of entities, risk, and targets in clinical routine. Clin Cancer Res. 2011;17(23): 7240-7247.
39. Domschke C, Schuetz F, Ge Y, et al. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis. Cancer Res. 2009;69(21):8420-8428.
40. Guckel B, Stumm S, Rentzsch C, Marme A, Mannhardt G, Wallwiener DA. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A∗02-matched situations in vitro as well as in vivo. Cancer Immunol Immunother. 2005; 54(2):129-140.
41. Voss RH, Thomas S, Pfirschke C, et al. Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of singlechain TCR-transduced human T cells. Blood. 2010;115(25):5154-5163.
42. Nummer D, Suri-Payer E, Schmitz-Winnenthal H, et al. Role of tumor endothelium in CD41 CD251 regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst. 2007;99(15): 1188-1199.
43. Bai L, Beckhove P, Feuerer M, et al. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer. 2003;103(1):73-83.
44. Solomayer EF, Feuerer M, Bai L, et al. Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer. Clin Cancer Res. 2003;9(1):174-180.
45. Sivan S, Suzan F, Rona O, et al. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol. 2012;2012:290536.
46. Hasselbalch HC, Skov V, Larsen TS, et al. High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis. Leuk Res. 2011;35(10): 1330-1334.
47. Maraqa L, Cummings M, Peter MB, Shaaban AM, Horgan K, Hanby AM, Speirs V. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res. 2008;14(2): 405-411.
48. Li J, Sze DM, Brown RD, et al. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood. 2010; 115(17):3580-3588.
49. Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine. 2007;25(Suppl 2): B72-B88.
50. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-264.
51. Lee HS, Ostrowski MA, Gray-Owen SD. CEACAM1 dynamics during neisseria gonorrhoeae suppression of CD41 T lymphocyte activation. J Immunol. 2008;180(10):6827-6835.
52. Lin J, Weiss A. T cell receptor signalling. J Cell Sci. 2001;114(Pt 2):243-244.
53. Latour S, Fournel M, Veillette A. Regulation of T-cell antigen receptor signalling by Syk tyrosine protein kinase. Mol Cell Biol. 1997;17(8): 4434-4441.
54. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010;185(11):6413-6419.
55. Lasa A, Serrano E, Carricondo M, et al. High expression of CEACAM6 and CEACAM8 mRNA in acute lymphoblastic leukemias. Ann Hematol. 2008;87(3):205-211.
56. Jantscheff P, Terracciano L, Lowy A, et al. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol. 2003;21(19): 3638-3646.